Skip to main content
Premium Trial:

Request an Annual Quote

Evogen Raises $3M in VC Funding Round

NEW YORK (GenomeWeb News) – Molecular diagnostics firm Evogen said this week that it has raised $3 million in a series B round of venture capital funding.
 
The round was led by New York-based venture capital firm L Capital Partners.
 
Evogen, which formerly was named Sceptor Industries, is developing a PCR-based diagnostics instrument called the EvoCycler HD12. The Kansas City, Mo.-based firm said the instrument costs 50 percent less than instruments with similar capabilities and is small enough to fit on a desktop.
 
After the anthrax scare of 2001, the US Postal Service had installed Sceptor’s SpinCon aerosol collection device in every mail-sorting center nationwide, according to Evogen. The firm said that the firm now can combine Sceptor’s aerosol collection technology with molecular diagnostics for use in a variety of applications.
 
“Our portfolio of technologies and applications allow us to further expand beyond the biodefense market into commercial markets, including clinical diagnostics, environmental testing, and research,” Evogen President and CEO Sean Reineke said in a statement.

The Scan

Push Toward Approval

The Wall Street Journal reports the US Food and Drug Administration is under pressure to grant full approval to SARS-CoV-2 vaccines.

Deer Exposure

About 40 percent of deer in a handful of US states carry antibodies to SARS-CoV-2, according to Nature News.

Millions But Not Enough

NPR reports the US is set to send 110 million SARS-CoV-2 vaccine doses abroad, but that billions are needed.

PNAS Papers on CRISPR-Edited Cancer Models, Multiple Sclerosis Neuroinflammation, Parasitic Wasps

In PNAS this week: gene-editing approach for developing cancer models, role of extracellular proteins in multiple sclerosis, and more.